Indication Expansion Strategy for Biotech Assets and Platforms
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Decision questions
What this solution is built to answer.
Which indications should enter the shortlist and why?
Which opportunities have biological rationale but poor commercial or clinical feasibility?
How should a platform sequence indications under capital constraints?
Which candidates deserve go, hold, kill, or deeper assessment?
Science and method
What can change the model or gate.
Broad indication scan across 10-30 candidates.
Deep assessment of a 3-5 indication shortlist.
Board-grade expansion roadmap for the final 1-2 indications.
Scientific, commercial, competitive, regulatory, IP, and valuation scoring lanes.
Target-indication matrix script for repeatable scoring visuals.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| indication-expansion-scan | Broad-universe triage | INDICATION__SCAN, target-indication matrix, shortlist |
| indication-expansion-assessment | Deep per-indication assessment | INDICATION__ASSESSMENT with score and verdict |
| indication-expansion-strategy | Committee sequencing and roadmap | INDICATION__STRATEGY_DOSSIER, roadmap, risk register |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Ranked indication shortlist.
Target-indication scoring matrix.
Per-indication evidence and caveat table.
Expansion roadmap with investment plan and sequencing logic.
Proof points
Indication workflows are split into scan, assessment, and strategy tiers.
The workflow can combine biology, trials, IP, regulatory, competition, and valuation rather than ranking on one dimension.
The scoring matrix is backed by a reusable script path.
Limits and review conditions
What this result does not establish.
Unsupported economics remain a visible gap. ARiDA does not manufacture a market value to complete a ranking.
FAQ
Common evaluation questions.
Is indication expansion just market sizing?
Market size matters, but ARiDA also stages biological rationale, clinical feasibility, competitive density, IP context, regulatory path, and valuation implications.
Can a broad scan become a board roadmap?
Yes. The workflow family is tiered so broad scans can move into deep assessment and then into an expansion strategy dossier.
Related solutions
Clinical Trial Intelligence
Analyze trial landscapes, protocol patterns, endpoints, enrollment signals, sponsor behavior, recent registry changes, and historical AACT structure.
Systematic Review
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Biotech Valuation
Connect scientific evidence and uncertainty to PoS, rNPV, option value and the asset or portfolio decision under review.
Related reading
Evaluate indication expansion without hiding the weak dimension
Rank biology, clinical feasibility and economics while keeping hard gates and missing evidence separate.
Build the decision case before the committee deck
A committee document is credible only when the evidence, assumptions and alternatives exist underneath it.
Triage a portfolio without turning judgment into a score
Use hard gates, uncertainty and resource constraints to expose the real allocation choice.